Data as of Jan 29
| +0.04 / +0.42%|
The 6 analysts offering 12-month price forecasts for Merrimack Pharmaceuticals Inc have a median target of 13.50, with a high estimate of 16.00 and a low estimate of 11.00. The median estimate represents a +41.21% increase from the last price of 9.56.
The current consensus among 7 polled investment analysts is to Buy stock in Merrimack Pharmaceuticals Inc. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.